Allianz Asset Management
KNSA icon

Allianz Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Allianz Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,500
Closed -$389K – 2165
2025
Q1 		$389K Sell
17,500
-6,000
-26% -$123K ﹤0.01% 1957
2024
Q4 		$465K Buy
23,500
+14,700
+167% +$336K ﹤0.01% 1886
2024
Q3 		$220K Buy
+8,800
New +$214K ﹤0.01% 2060

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Allianz Asset Management's KNSA Position: Q2 2025 in Review

Allianz Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 17,500 shares — an estimated $389K sold.

Allianz Asset Management first reported a position in KNSA in Q3 2024 and held it in 3 quarters. The position peaked at $465K in Q4 2024. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • Allianz Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 17,500 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $389K.
  • Allianz Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Allianz Asset Management's Kiniksa Pharmaceuticals position peaked at $465K in Q4 2024.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.